Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019603 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
A Phase 1 study of Acne Vulgaris, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01019603 is a Phase 1 study of Acne Vulgaris that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 30 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01019603, a Phase 1 study of Acne Vulgaris, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess systemic exposure of a new foam formulation of tazarotene, 0.1% compared with Tazorac Gel, 0.1%. The study design and dosing regimen are based on previous clinical studies with Tazorac Gel and Tazorac Cream.
Conditions Studied
Interventions
- DRUG Tazarotene
- DRUG Tazaroc Gel
Study Locations (1)
Texas
- DermResearch, Inc. - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-10-12 |
| Est. Completion | 2009-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01019603
The ClinicalTrials.gov registry entry for NCT01019603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (89% lower). The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Tazarotene is the first listed.
NCT01019603 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01019603 about?
NCT01019603 is a clinical study titled "A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris". The purpose of this study is to assess systemic exposure of a new foam formulation of tazarotene, 0.1% compared with Tazorac Gel, 0.1%. The study design and dosing regimen are based on previous clinical studies with Tazorac Gel and Tazorac Cream.
What is the current status of trial NCT01019603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-10-12. Estimated completion is 2009-12-20.
What conditions does trial NCT01019603 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT01019603?
The interventions under investigation include: Tazarotene (DRUG), Tazaroc Gel (DRUG).
Who is sponsoring clinical trial NCT01019603?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01019603 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Lipidome and Microbiome Profile of Acne
ACTIVE NOT RECRUITING · Phase 1
-
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
COMPLETED · Phase 1
-
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
COMPLETED · Phase 1
-
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
COMPLETED · Phase 1
-
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.